Ioflupane (123i) Rotop (Ioflupane (123i))

After intravenous injection, Ioflupane, which is labeled with the radioactive isotope iodine‑123, binds selectively to dopamine transporters on the surface of nigrostriatal neurons. The bound tracer emits gamma photons that are captured by a SPECT scanner, producing images that reflect the density and functional status of dopaminergic pathways in the brain.

The administered activity of Ioflupane (123i) Rotop is determined by the prescribing physician or nuclear medicine specialist based on patient weight, age, and the imaging protocol. The exact dose is individualized and should follow local regulatory guidelines and the product’s prescribing information.

Safety data for Ioflupane in pregnancy and lactation are limited, and the product is classified as having an unknown risk. It should only be used when the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and after careful consideration by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Ioflupane (123i) is one of several iodine‑123‑labeled ligands used for DAT imaging. Compared with alternatives such as 99mTc‑TRODAT‑1, Ioflupane offers high affinity for DAT and well‑characterized imaging protocols, making it a widely accepted choice in Europe and North America for evaluating Parkinsonian syndromes.

Ioflupane (123i) Rotop must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The vial should remain in its original packaging until use, and all handling must comply with local radiation safety regulations.

The product is supplied as a sterile injectable solution for intravenous administration. It is injected as a single bolus dose under the supervision of a qualified nuclear medicine physician or radiologist, after which the patient undergoes SPECT imaging at a predetermined time interval.

Serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, radiation‑induced skin injury at the injection site, and rare neurologic events like seizures. Patients should be monitored closely during and after injection, and emergency measures should be readily available.

Ioflupane is contraindicated in individuals with known hypersensitivity to iodine‑123 or any component of the formulation, and in patients for whom the diagnostic information would not influence clinical management. Caution is also advised for those with severe renal impairment or uncontrolled hypertension.